Education
About Us
Working with TipRanks
Follow Us
Mesoblast Ltd (MESO)
NASDAQ:MESO
MESO Stock Chart & Stats
$14.55
-$0.53(-2.96%)
At close: 4:00 PM EST
$14.55
-$0.53(-2.96%)
Day’s Range― - ―
52-Week Range$9.61 - $21.50
Previous CloseN/A
Volume155.35K
Average Volume (3M)186.13K
Market Cap
$1.89B
Enterprise Value$1.79B
Total Cash (Recent Filing)$161.16M
Total Debt (Recent Filing)$128.16M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Sep 02, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding129,030,210
10 Day Avg. Volume168,431
30 Day Avg. Volume186,128
Financial Highlights & Ratios
PEG Ratio2.44
Price to Book (P/B)2.20
Price to Sales (P/S)76.48
P/FCF Ratio-25.95
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue104.23
Enterprise Value/Gross Profit-49.99
Enterprise Value/Ebitda-30.81
Forecast
1Y Price Target
$35.00Price Target Upside140.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.06
Revenue Forecast (FY)$127.12M
Bulls Say, Bears Say
Bulls Say
High‑margin Product LaunchRyoncil’s initial commercial sales generated material top‑line contribution with very high reported gross margins. Durable high margin on product sales supports reinvestment in commercialization and clinical programs, improving cash conversion per sale as volumes scale over the next 2–6 months.
Broad Payer & Center AccessExtensive payer coverage, a specific J‑code and early onboarding of transplant centers reduce reimbursement and access barriers. These structural access levers materially increase likelihood of sustained uptake and quicker penetration in pediatric markets and facilitate later adult label expansion.
Solid Liquidity And Financing FlexibilityA strong cash balance plus a sizable, non‑dilutive credit facility provide runway to scale commercial operations, complete CMC activities and progress registrational trials without immediate equity issuance. This financing flexibility materially lowers short‑term dilution and supports execution through key near‑term milestones.
Bears Say
Ongoing Losses And Cash BurnConsistent operating losses and meaningful cash consumption highlight that profitability remains distant. Even with improving trends, sustained negative operating cash flow increases reliance on financing and requires durable revenue growth to avoid recurring capital raises that could dilute stakeholders or constrain strategic optionality.
Concentration On Single ProductRevenue is heavily dependent on one newly launched therapy; any setbacks in uptake, reimbursement changes or supply issues would materially impact cash generation. Until label expansion or other pipeline products contribute, this concentration creates persistent execution and commercial risk for the company.
Rising R&D And SG&A From ScalingSharp increases in R&D and commercial spend reflect necessary investments to advance registrational programs and scale sales. But higher structural operating expenses raise break‑even needs and pressure cash runway if revenue growth slows, making sustained margin expansion contingent on successful launches and cost discipline.
Mesoblast News
MESO FAQ
What was Mesoblast Ltd’s price range in the past 12 months?
Mesoblast Ltd lowest stock price was $9.61 and its highest was $21.50 in the past 12 months.
What is Mesoblast Ltd’s market cap?
Mesoblast Ltd’s market cap is $1.89B.
When is Mesoblast Ltd’s upcoming earnings report date?
Mesoblast Ltd’s upcoming earnings report date is Sep 02, 2026 which is in 182 days.
How were Mesoblast Ltd’s earnings last quarter?
Mesoblast Ltd released its earnings results on Feb 25, 2026. The company reported -$0.311 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.241.
Is Mesoblast Ltd overvalued?
According to Wall Street analysts Mesoblast Ltd’s price is currently Undervalued.
Does Mesoblast Ltd pay dividends?
Mesoblast Ltd does not currently pay dividends.
What is Mesoblast Ltd’s EPS estimate?
Mesoblast Ltd’s EPS estimate is -0.06.
How many shares outstanding does Mesoblast Ltd have?
Mesoblast Ltd has 129,030,210 shares outstanding.
What happened to Mesoblast Ltd’s price movement after its last earnings report?
Mesoblast Ltd reported an EPS of -$0.311 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went up 0.059%.
Which hedge fund is a major shareholder of Mesoblast Ltd?
Currently, no hedge funds are holding shares in MESO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesoblast Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (140.55% Upside)
$35.00 (140.55% Upside)
Blogger Sentiment
Bullish
MESO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 12.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 3.5%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Bullish
Bullish news 60%
Bearish news 40%
Bearish news 40%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.39%
12-Months-Change
Fundamentals
Return on Equity
-18.24%
Trailing 12-Months
Asset Growth
19.74%
Trailing 12-Months
Company Description
Mesoblast Ltd
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
MESO Company Deck
MESO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed strong commercial momentum following the successful Ryoncil launch (USD 49M H1 revenue, 93% gross margin), meaningful market access achievements (coverage for >280M lives, J-code, centers onboarded), robust cash and financing flexibility (USD 130M cash and new USD 125M facility), and compelling randomized data for Revascor and progress on rexlemestrocel-L. Offsetting these positives are sharp increases in R&D and SG&A as the company scales commercialization and advances clinical programs, continued operating losses and notable dependency on a single launched product while other programs mature. Overall, the call emphasized execution progress, regulatory engagement, and a clear path for near-term milestones, with manageable financial and execution risks.View all MESO earnings summariesMESO Stock 12 Month Forecast
Average Price Target
$35.00
▲(140.55% Upside)
Technical Analysis
Sarepta Therapeutics
―
Cogent Biosciences
―
Adaptive Biotechnologies
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.21% Other Institutional Investors
99.30% Public Companies and
Individual Investors